The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2005Inhibitors of Poly (ADP-Ribose) Glycohydrolase (PARG) as Novel Agents for the Treatment of PD
It has become increasingly clear that the death of mid-brain neurons in Parkinson's disease patients is associated with the activation of certain enzymes that add sugar units onto various proteins. In...
-
Clinical Discovery Awards, 2005Phase I Study of CERE-120 [Adeno-Associated Virus (AAV)-Neuturin (NTN)] to Assess the Safety and Tolerability of Intraputaminal Delivery
Objective/Rationale:
Neurotrophic factors including neurturin (NTN) have been shown to effectively augment the function and prevent the death of dopaminergic nigrostriatal neurons in animal models of... -
MJFF Research Grant, 2005Nebraska Parkinson's Disease Registry
The American Parkinson Disease Association (APDA) and The Michael J. Fox Foundation for Parkinson's Research (MJFF) are co-funding the Nebraska Parkinson's Disease Registry with a three-year...
-
LEAPS, 2005Michael J. Fox Foundation Validation Study
The role of genetics in PD continues to be a major focus in the field and much of what we know about possible underlying mechanisms of PD cause and pathogenesis has come through studies of genes (e.g...
-
Molecular Mechanisms of Dyskinesia in Parkinson's Disease, 2005Mechanisms of Graft-Induced Dyskinesias in an Animal Model of Parkinson's Disease (Supplemental Funding)
Our ongoing project has four aims:
- To develop a model of graft-induced dyskinesia (GID) in the rat, which will provide a cost-effective tool for studying the mechanisms of this complication;
- To...
-
The Role of Inflammation in Parkinson's Disease, 2005Development of a Dominant-Negative TNF Lentiviral Approach
Because TNF inhibitors are not believed to cross the blood-brain barrier, an orally administered TNF-based therapy is not currently possible. The Foundation has awarded supplemental funding to drive...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.